Claims
- 1. A compound of the formula:
- 2. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt according to claim 1, and at least one pharmaceutically acceptable carrier or excipient.
- 3. A method for enhancing the therapeutic efficacy of an anti-infective agent in an animal, comprising administering to the animal the pharmaceutical composition of claim 2 in an amount effective to inhibit drug transport from an infectious agent in the animal.
- 4. A method for enhancing the delivery of a therapeutic agent to target cells or tissues of an animal, comprising administering to the animal the pharmaceutical composition of claim 2 in an amount effective to enhance delivery of the therapeutic agent to the target cells or tissues of the animal.
- 5. The method of claim 4, wherein the target cells or tissues are brain, testes, eye, or leukocytes.
- 6. A method for enhancing the absorption of an orally-delivered therapeutic agent in target cells or tissues of an animal, comprising administering to the animal the pharmaceutical composition of claim 2 in an amount effective to enhance drug transport across the gastrointestinal tract.
- 7. A compound of the formula:
- 8. A compound according to claim 7, wherein
- 9. A compound according to claim 8, wherein
R2 is methyl or benzyl.
- 10. A pharmaceutical composition comprising a compound of the formula:
- 11. A pharmaceutical composition according to claim 10, wherein
- 12. A pharmaceutical composition according to claim 10, wherein
R2 is methyl or benzyl.
- 13. The pharmaceutical composition of claim 10 further comprising at least one additional chemotherapeutic agent.
- 14. The pharmaceutical composition according to claim 13, wherein the additional chemotherapeutic agent is selected from the group consisting of dihydropyridines, thioxanthenes, phenothiazines, cyclosporins, acridonecarboxamides, verapamil, cyclosporin A, PSC 833, tamoxifen, quinidine, quinine, bepridil, ketoconazole, megestrol acetate, and estramustine.
- 15. A method for inhibiting drug transport from target cells or tissues in an animal undergoing chemotherapy, comprising administering to the animal the pharmaceutical composition of claim 10 in an amount effective to inhibit drug transport.
- 16. The method of claim 15, wherein drug transport is mediated by P-glycoprotein.
- 17. A method according to claim 16, which further comprises administering a second chemotherapeutic agent.
- 18. A method according to claim 17, wherein the second chemotherapeutic agent is selected from the group consisting of dihydropyridines, thioxanthenes, phenothiazines, cyclosporins, acridonecarboxamides, verapamil, cyclosporin A, PSC 833, tamoxifen, quinidine, quinine, bepridil, ketoconazole, megestrol acetate, and estramustine.
- 19. A method for preventing drug resistance in target cells or tissues in an animal undergoing chemotherapy, comprising administering to the animal the pharmaceutical composition of claim 10 in an amount effective to attenuate drug resistance in the target cells or tissues of the animal.
- 20. A method for enhancing the therapeutic efficacy of an antiproliferative drug in target cells or tissues of an animal undergoing chemotherapy, comprising administering to the animal the pharmaceutical composition of claim 10 in an amount effective to enhance delivery of the antiproliferative drug to the target cells or tissues of the animal.
Parent Case Info
[0001] This application is a continuation of U.S. Provisional Patent Application Nos. 60/193,109, filed on Mar. 30, 2000, and 60/193,104, filed on Mar. 30, 2000, the disclosure of each of which is explicitly incorporated by reference herein.
Government Interests
[0002] This invention was made with government support Grant CA64983 awarded by the United States Public Health Service. The government has certain rights in the invention.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60193109 |
Mar 2000 |
US |
|
60193104 |
Mar 2000 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09822743 |
Mar 2001 |
US |
Child |
10396070 |
Mar 2003 |
US |